SCHEMBL8445549

SCHEMBL8445549

CC1CC(=O)CC(=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
NR1H2 P55055 1/20 0.33
SCN9A Q15858 1/20 0.33
MAPK1 P28482 1/20 0.33
GLA P06280 1/20 0.33
HPGD P15428 1/20 0.33
KLK7 P49862 1/20 0.32
ELANE P08246 1/20 0.32
GPR119 Q8TDV5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23902600 1.00 CHRM2 (0.39) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL21470687 1.00 CHRM2 (0.39) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL483259 0.86 CHRM2 (0.43) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL20406585 0.86 CHRM2 (0.43) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL25489357 0.82 CHRM2 (0.38) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL28806067 0.81 CHRM2 (0.37) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL29796406 0.81 CHRM2 (0.37) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL31080065 0.80 GLA (0.38) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL31080746 0.80 CHRM2 (0.36) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL29701788 0.78 MMP2 (0.42) CHRM2CHRM1CHRM3KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-05 US disclosed
CN-117897382-A Nitrogen-containing tricyclic compounds and pharmaceutical uses thereof 日本烟草产业株式会社 2024-04-16 CN disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
WO-2021198020-A1 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2021-10-07 WO disclosed
EP-2380890-A1 New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors Almirall, S.A. (ES) 2011-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 CHRM2 3335/4885CHRM1 4620/4885CHRM3 4128/4885
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 CHRM2 3335/4885CHRM1 4620/4885CHRM3 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.